trending Market Intelligence /marketintelligence/en/news-insights/trending/nRzezB0MMU03t16LKFfCdA2 content esgSubNav
In This List

Pfizer enters collaboration to discover novel therapeutic antibodies

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Pfizer enters collaboration to discover novel therapeutic antibodies

Pfizer Inc. entered into a collaboration with Ab Initio Biotherapeutics Inc. to discover novel therapeutic antibodies against an undisclosed target in the G-protein coupled receptor superfamily.

G-protein coupled receptors comprise the largest class of therapeutic drug targets, with key regulatory roles in physiological processes ranging from cardiovascular biology to metabolic health.

Ab Initio will be using its antibody discovery platform to help engineer the antibodies that activate the targeted receptor. It will also receive an up-front fee and research support and is eligible for milestone payments and tiered royalties on future sales of products resulting from the collaboration.

As part of this transaction, Ab Initio added Will Somers, vice president of biomedicines design at Pfizer, to the Ab Initio scientific advisory board.

Additional terms of the deal were not disclosed.

Pfizer will also make a strategic investment in Ab Initio alongside the company's existing investors.